Showing results (1231-1240 of 1,274) with videos related to

Sort By:
Pageof 128
Neurology|December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow TransplantationJeffrey A Cohen, Laura E Baldassari, Harold L Atkins, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 1997
Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptorS Patel, S Freedman, K L Chapman, et al.
Brain Imaging and Behavior|August 30, 2018
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometryKerstin Bendfeldt, Bernd Taschler, Laura Gaetano, et al.
Lancet (London, England)|June 14, 2016
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trialHarold L Atkins, Marjorie Bowman, David Allan, et al.
Clinical and Translational Science|May 13, 2021
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory considerationHongbing Wang, Paul C Brown, Edwin C Y Chow, et al.
Annals of Clinical and Translational Neurology|March 22, 2018
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS studyDavid H Miller, Fred D Lublin, Maria Pia Sormani, et al.
Nature Communications|October 24, 2015
Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroidsBenjamin S Freedman, Craig R Brooks, Albert Q Lam, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyBarry A Singer, Douglas L Arnold, Jelena Drulovic, et al.
The Lancet. Oncology|July 19, 2024
Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trialYaacov R Lawrence, Marcin Miszczyk, Laura A Dawson, et al.
Pageof 128